Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.

Abstract

It is still unclear whether there are clinically exploitable differences in the biology and behaviour of early versus late relapses in diffuse large B-cell lymphoma (DLBCL). The present study aimed to analyse a large population-based DLBCL cohort in order to identify (i) the frequency of late relapses (LR), (ii) parameters influencing the risk of LR, and… (More)
DOI: 10.1111/bjh.14822

Topics

  • Presentations referencing similar topics